Recommendation from Healthcare Sector

This section gives a recommendation of a stock having stock price below Rs 150 with sound fundamentals and expected to give handsome returns over a one-year time horizon [EasyDNNnews:PaidContentStart]

Amanta Healthcare Ltd. : NICHE PHARMA STOCK WITH EXPANSION TRIGGERS

HERE IS WHY
✓  Niche sterile liquids play
✓  SterIPOrt expansion to boost growth
✓  Solar savings to aid margins

I n healthcare, some of the most essential products work behind every treatment. Intravenous fluids, sterile injectables, diluents, eye care solutions and respiratory formulations may not command the spotlight, but they are indispensable in hospitals, ICUs, emergency rooms and operating theatres. The industry rewards safety, sterility and reliable supply. Amanta Healthcare fits into this specialised space as a focused sterile liquids manufacturer. Its strength lies in Large Volume Parenterals and Small Volume Parenterals, supported by its flagship SteriPort platform. In a segment where contamination risk can affect patient safety, Amanta has built its position through container integrity, advanced manufacturing and hospital acceptance.

Amanta Healthcare is a three decade old company focused on sterile liquid products. It operates from a WHO GMP certified facility in Gujarat. The company has built a balanced model across branded domestic sales, exports and loan licence manufacturing. Its domestic reach is supported by more than 320 distributors and stockists, while its international presence extends to 21 countries. With 47 products registered across 120 international jurisdictions, Amanta has a platform that can support growth.

The company’s portfolio serves hospital and clinical requirements across fluid therapy, injectable formulations, diluents, ophthalmic care, respiratory care and irrigation solutions. These products are used for hydration support, drug delivery, infection treatment, eye care, respiratory therapy and medical cleaning applications. The portfolio includes volume driven products and higher value formulations. Over time, the company has moved towards better realisation categories such as eye drops, respiratory solutions and export focused products, which can improve margins and reduce dependence on low value diluent led growth.

The next growth phase is expected to come from capacity expansion, operating leverage and cost savings. Amanta is scaling SteriPort capacity from 6.6 crore bottles to near 12 crore bottles per annum, with go live expected in Q1FY27. SVP capacity is being raised from about 21 crore units to nearly 31 crore units by January 2027, lifting its better margin export mix. The company is setting up a 10.8 MW solar captive power plant, expected to be commissioned by Q1FY27 and save around ₹9 crore each year at EBITDA level. Higher utilisation and export growth can support margins.

Financially, the company appears to be moving from an investment led phase to a stronger profitability phase. In Q3FY26, revenue stood at around ₹75 crore, registering 9.8 per cent YoY growth, while EBITDA came in at ₹15 crore with a margin of about 21 per cent. PAT stood at around ₹5 crore, up 8.1 per cent YoY. For 9MFY26, revenue stood at ₹211 crore, EBITDA was ₹45 crore and PAT grew around 51 per cent YoY to ₹9 crore.

Key risks include delay in capacity ramp up, slower export approvals, raw material cost pressure, working capital intensity and execution challenges in product scale up. As Amanta operates in sterile manufacturing, any quality, compliance or regulatory issue can impact growth, margins and customer confidence.

At a PE of 34.8x, Amanta is not inexpensive on a plain earnings multiple. However, the PEG ratio of 0.84x makes the valuation more reasonable when seen against expected growth. Its price to sales ratio of 1.96x also compares favourably with the median industry level of 3.4x. The company offers a niche sterile liquids platform, hospital led demand, capacity expansion, export opportunity and visible cost savings from solar power. With scale benefits likely to flow through, the outlook remains positive. Keeping all the above factors in mind, we recommend Buy.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

[EasyDNNnews:UnPaidContentEnd]